Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 29Carcinoma, Renal Cell 17Liver Neoplasms 12Breast Neoplasms 10Carcinoma, Non-Small-Cell Lung 9Neoplasms 5Leukemia, Myeloid, Acute 5Kidney Neoplasms 5Neoplasm Metastasis 4Urinary Bladder Neoplasms 3Thyroid Neoplasms 3Prostatic Neoplasms 3Lung Neoplasms 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Lymphocytic, Chronic, B-Cell 3Colorectal Neoplasms 3Carcinoma 3Thyroid Carcinoma, Anaplastic 2Thyroid Cancer, Papillary 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Myelodysplastic Syndromes 2Multiple Myeloma 2Breast Neoplasms, Male 2Blast Crisis 2Adenocarcinoma, Follicular 2Urethral Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Thyroid cancer, medullary 1

Interventions

Gemcitabine 11Cisplatin 8pembrolizumab 2Oxaliplatin 2Nivolumab 2Docetaxel 2Capecitabine 2trametinib 1titanium silicide 1telotristat ethyl 1sovateltide 1niraparib 1milademetan 1folfirinox 1dostarlimab 1devimistat 1cytokine inducible SH2-containing protein 1brigimadlin 1bintrafusp alfa protein, human 1becatecarin 1adagrasib 1Sorafenib 1S 1 (combination) 1Pancreaticojejunostomy 1NUC-1031 1Leucovorin 1Hydroxychloroquine 1Fluorouracil 1Cetuximab 1Catheter Ablation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Biliary Tract Neoplasms × Sorafenib × Clear all
NCT00955721 2018-01-03

A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer

University of Miami

Phase 1/2 Terminated
9 enrolled 7 charts
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡